Purpose To study the safety and effectiveness of sclerotherapy with 3% sodium tetradecyl sulfate (STS) in the management of venous malformation (VM) of the tongue.
Introduction
Venous malformations (VMs) of the tongue occur due to defective vascular morphogenesis; hence they are present at birth but can manifest clinically at any age. 1 Similar to VMs in other locations, these are postcapillary lesions and exhibit slow flow. 2 The lesions are soft, nonpulsatile, compressible, and position dependent. They often have a bluish tinge and enlarge in size on Valsalva's maneuver. 3 They are responsive to hormones and may enlarge during physical exertion and pregnancy. 4 These lesions cause cosmetic disfiguration, recurrent hemorrhage, and pain. They can also cause functional impairment of speech, chewing, swallowing, and breathing. 5 They progressively enlarge with age, fail to regress, and are a challenge to treat. 6 The goal of therapy for symptomatic VMs of the tongue is to reduce the size of the malformation and conserve as much lingual tissue as possible. There are limited data on the management of tongue VMs. Treatment options include surgical excision, laser therapy, cryotherapy, radiotherapy, embolization, sclerotherapy, and medical treatment with interferon-α and steroids. 2 These options are often combined to achieve optimal results. There are no comparative studies assessing the efficacy of these treatment methods.
Sclerotherapy is minimally invasive and inexpensive. Sodium tetradecyl sulfate (STS) acts by destroying the endothelial lining of the VM and coagulates the intraluminal blood resulting in obliterative thrombosis. 7, 8 This is followed by fibrosis and reduction in the lesion size. 9 In this study, we report our experience on treating VM of tongue with sclerotherapy using 3% STS.
Materials and Methods
This retrospective study was approved by our institutional review board. The clinical and imaging data of patients with tongue VMs, treated with STS sclerotherapy over a period of 15 years (2002-2017) were reviewed. Data collected included patient demographics, presenting symptoms, number of treatment sessions, quantity of sclerosant, improvement, and complications. Improvement was assessed by reduction in the lesion size and symptom relief after a period of 1 year.
Diagnosis
The diagnosis of VM was based on history, clinical examination, and imaging findings on ultrasound (US) and magnetic resonance imaging (MRI) (►Fig. 1). Clinical examination was performed to locate the lesion, determine its visible extent, and also to plan for access during the procedure. US evaluation was performed to confirm the presence of venous spaces that were amenable for sclerotherapy. All patients underwent MRI to confirm the diagnosis of VM and to define the extent of the lesion. The diagnostic features considered on MRI were high signal intensity on short tau inversion recovery (STIR) and T2-weighted sequence. The VMs were categorized based on the size. Lesions greater than 3 cm were considered large. Small lesions were less than 1.5 cm. The lesions between 1.5 and 3 cm were considered medium in size. 7
Treatment
All procedures were performed under general anesthesia. The venous spaces were accessed with or without ultrasonography (USG), using either a 23G scalp vein (SV) or 22G
Chiba needles, such that the needle entered through the normal mucosa or the skin. When needed, the tongue was stretched outside using sponge-holding forceps covered with a gauze piece. Alternatively, a midline anterior suture was used avoiding area of the tongue involved by VM. If required, multiple needles were placed into different locations of the VM. The needles were confirmed to be within the venous spaces by observing free backflow of blood. Under fluoroscopic guidance, contrast material was injected through the needles to define the extent, volume, and pattern of venous drainage of the venous spaces. An equal volume of STS foam was considered for therapy. STS (3%) was mixed with same quantity of air to form STS foam using two10-mL disposable syringes connected via a three-way (modification of the standard Tessari method). 10 The STS foam was injected into the vascular spaces under fluoroscopic guidance using a blank roadmap (►Fig. 2). The dose of STS was 0.5 mL/kg up to a maximum dose of 20 mL per treatment.
Postprocedural Management
All patients who were extubated immediately after the procedure were observed in the recovery room until they became fully conscious. They were advised to hydrate well and were observed in the hospital for 6 hours. They were discharged after 6 hours if there were no complications. Patients with VMs involving the posterior third of the tongue or at a high risk for airway obstruction after the sclerotherapy were electively kept intubated in the intensive care unit (ICU) for up to 2 days postprocedure to ensure adequate airway.
Follow-up
All patients were seen every 3 months for clinical improvement and for planning subsequent treatment. During these visits, they were assessed clinically for reduction in the lesion size and relief of symptoms. An US evaluation was performed during every visit to evaluate the presence of venous spaces. Patients were counseled for further sessions of treatment. The study endpoint in terms of clinical improvement was at 1 year after treatment. 
Study Endpoints
Any reduction in the lesion size was considered as technical success whereas relief of presenting symptoms was considered as clinical success. Both technical and clinical successes were taken as clinical improvement and graded together on a scale of 0 to 10 on follow-up after 1 year. The patients who could not follow up in person were assessed for clinical improvement through a telephonic conversation. Any technical or clinical success was considered as effectiveness of the procedure (►Fig. 3). The complications were graded according to the Society of Interventional Radiology (SIR) grading system. 11
Results
Forty-four patients were included in this study. Twenty-six (59%) were men and 18 (41%) were women. The age ranged from 7 and 63 years. Most patients were in their second and fourth decades. Twelve patients were between 21 and 30 years. The median age was 24 years, whereas the mean age was 28.5 years. The most common clinical presentation was swelling of the tongue (41 of 44). The other predominant presenting symptoms were bleeding and pain. Of the 44 patients, 1 patient had an extensive abnormality that prevented complete closure of the mouth. Other symptoms such as difficulty in speech, swallowing, and breathing were less commonly seen (►Table 1).
Twenty-five (56%) patients had large (> 3 cm) VMs, 10 had medium-sized (1.5-3 cm) VMs, and 9 had small VMs (< 1.5 cm). The smallest lesion treated measured 0.5 × 0.5 cm, and the largest lesion was 8.5 × 5.5 cm. Mean size of the lesion was 3.8 cm with a standard deviation (SD) of 2.02 cm. The portions of the tongue most frequently involved were the lateral aspects (22 of 44; 50%), followed by the anterior aspect (15 of 44; 34%). Four (9%) patients had involvement of the posterior aspect of the tongue, two (5%) ventral aspect involvement, and the VM was diffuse in one (2%) patient (►Fig. 4).
The number of treatment sessions ranged from 1 to 7. The median number of treatment sessions for the different portions of the tongue was one. There was no significant difference (p = 0.38) in the number of treatment sessions based on the location of the lesion. Half of the study population (22 of 44) underwent only a single treatment session (►Fig. 5). For the large, medium, and small lesions, the median numbers of treatment sessions were 1, 2, and 1, respectively. There was no significant correlation (p = 0.94) between the lesion size and the number of treatment sessions on Spearman's rank correlation test. The amount of sclerosant used varied from 0.5 to12 mL (mean 3.7 2.5).
Four patients received elective intubation in anticipation of airway obstruction. Of these four patients, only one patient who had large diffuse involvement of the tongue required prolonged intubation up to 72 hours due to significant postprocedure swelling. A transient increase in the lesion size was seen in all patients (►Fig. 3).
Follow-up was a challenge as most patients were from distant places. Of the 44 patients, 22 were seen in person, whereas 14 were reviewed through a telephonic conversation and graded for clinical improvement on a scale of 0 to 10 after 1 year. Eight patients were lost to follow-up (►Table 2). Among 36 patients, 30 (83%) had clinical improvement with sclerotherapy (►Table 3). The median clinical improvement was 4.5 on the 10-point scale, with a range of 1 to 8. Twelve (12 of 36, 33.3%) patients demonstrated 1 to 40% improvement in the lesion size and 18 (50%) had 41 to 80% improvement in the lesion size.
Complications
Complications were noted in four (9%) patients. Two patients had minor complications whereas two had major complications (►Table 4).
Discussion
In our study, sclerotherapy of the VM of the tongue with 3% STS was found to be effective in majority (30 of 36, 83%) of the patients. No patient reported worsening of symptoms during follow-up.
We have used 3% STS in all the patients. STS has relatively smaller incidence of major complications as compared with a more potent sclerosant, absolute alcohol. 12 Bleomycin is the other choice of sclerosant with reportedly less post-treatment swelling. 13, 14 However, a risk of pulmonary fibrosis is associated with bleomycin, which has been mainly studied regarding chemotherapy.
The amount of endothelial effect and subsequent inflammation should ideally be such that the VM should be sclerosed with minimum number of treatment sessions. At the same time, the swelling caused as a component of inflammation should not result in complications. We believe the treatment effect is multifactorial, including the choice of sclerosant, volume of sclerosant, and dwell time of the sclerosant to act on the endothelial lining of the VM. Because we performed all the procedures under general anesthesia, tongue muscle relaxation would have contributed to better dwell time. Although the nature of the VM in the tongue is similar to the VMs elsewhere in the body, sclerotherapy of the tongue is challenging. While intubating the patient, the site of sclerotherapy needs to be discussed with the anesthetist, so that the endotracheal tube does not come in the way of sclerotherapy. It is a unique requirement to pull the tongue out to access the VM. We applied two different techniques as mentioned in the methodology. We avoided placing a suture to pull the tongue out if the anterior portion of the tongue was involved by the disease to prevent excess hemorrhage. When the patient is under anesthesia, muscle relaxation is an advantage, which results in enlargement of the lesion, facilitating better placement of the needles and also increasing the dwell time. Sometimes it may be difficult to use US guidance for accurate placement of the needles because of the limited place to keep both the probe and needle. In such situations, one could use US to locate the abnormal region and then puncture the lesion with the needle without real time US guidance and depend on the backflow of the blood to the needle to ensure proper placement of the needle tip within the venous space. Furthermore, this could be confirmed by venography. Proximity to the airway, especially when the posterior part of the tongue is involved, makes a huge difference, when compared with a similar VM in the extremity. We encountered only a few complications, which occurred in 4 (9%) of 44 patients. In only one patient, there was profuse bleeding from the tongue when silk thread was used to pull the tongue out. This particular complication, though extremely rare, should be kept in mind, and backup facilities such as transarterial embolization and surgery should be available. Hematuria was seen in only one patient, which could be due to relatively smaller amount of STS used in each sclerotherapy. Severe swelling and compromise of the airway requiring prolonged intubation was observed in one patient, who had a large and diffuse VM of the tongue. Need for emergency tracheostomy has been reported by other authors, 15 who also noted that the lesions located posteriorly are at higher risk of complication. If a higher chance of airway compromise is anticipated, even a prophylactic tracheostomy may be considered. 15 An unusual case of development of squamous cell carcinoma of the tongue after sclerotherapy for the VM has been reported. 16 The published literature on sclerotherapy of tongue VMs are part of a spectrum among VMs in broader locations such as the head and neck or isolated case reports. 15, 17 There is need for prospective studies on sclerotherapy of the tongue with long-term follow-up.
There are many limitations to our study. First, this is a retrospective single-center study with a relatively small number of patients. Second, the follow-up is limited with a large number of patients followed only through telephonic interview. Many patients had only a single sitting of injection, which could be attributed either to financial constraints, distance, or satisfaction with partial improvement. Most of the follow-up was only clinical, without imaging; hence a comparative volumetry could not be performed.
Conclusion
Tongue VMs pose unique challenges for treatment, including proximity to the airway and difficulties with anesthesia. Percutaneous sclerotherapy with 3% STS is a simple, safe, and effective treatment for these patients. When the lesion is diffuse, one must be aware of airway compromise and be prepared for prolonged intubation.
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